感染症と治療ジャーナル

抽象的な

Quinine in Covid-19 Repurposing for Impact

Bisi Bright, Patrick O Sobande, Akinniyi Fajimi and Oluwatoyin Adesope

Quinine repurposing for use in moderate to severe COVID-19 is empirically utilized on a physician-patient basis, adduced from the
(LWI) study protocols for COVID-19 Response, a monologue of protocols which had been hypothesis-tested, and debated for 6 weeks
prior. The three (3) sets of study protocol S6 were compiled with a goal to arriving at a practical and affordable solution to the pandemic.
Having undergone debates and hypothesis testing among physicians, researchers and virologists, they are still undergoing random
physician-patient trials at the discretion of prescribers and researchers.
They are study protocols designed to ‘evolve’ as a solution to COVID-19 response. Having tested for the repurposing of Chloroquine
and Hydroxychloroquine. 1 in moderate to severe COVID-19 with little success, their use is now assigned to prophylaxis, for a future study.
The LWI study protocols strongly suggest the use of Quinine for COVID-19 treatment in moderate to advanced disease, recommending
intravenous infusion of Quinine for critical care in COVID-19.
In conclusion, although the sample size of the preliminary study was small, Quinine is impactful with positive outcomes for severe or
advanced COVID-19 especially after the cytokine storm, with 5-7 days total recovery after the onset of the cytokine storm. Our preliminary
study also found that CQ/HCQ may be very useful for prophylaxis and pre-emptive treatment in COVID-19. In furtherance to this study,
we are recommending strongly that a full study should be commissioned to establish